<div id="readability-page-1"><p>Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) has been given an average rating of &#34;Moderate Buy&#34; by the twenty-six research firms that are  covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one  has assigned  a strong buy rating to  the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $463.1326.</p><ul><li>Alnylam Stock Soars 65%: Find Out What’s Behind the Gains</li></ul><p>A number of brokerages have weighed in on ALNY. Citigroup began coverage on Alnylam Pharmaceuticals in a research note on Tuesday. They set a &#34;buy&#34; rating and a $380.00 price objective for the company. Needham &amp; Company LLC decreased their target price on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a &#34;buy&#34; rating for the company in a research note on Thursday, February 12th. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, May 2nd. Truist Financial lowered their price target on Alnylam Pharmaceuticals from $515.00 to $505.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, April 13th. Finally, Weiss Ratings raised Alnylam Pharmaceuticals from a &#34;sell (d+)&#34; rating to a &#34;hold (c-)&#34; rating in a report on Monday, May 4th.</p><p><b>Read Our Latest Research Report on ALNY</b></p><h2>Insider Activity at Alnylam Pharmaceuticals</h2><ul><li>3 biotech powerhouses poised to thrive amid sector rebound</li></ul><p>In other news, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $319.73, for a total value of $528,193.96. Following the completion of the sale, the executive vice president owned 21,860 shares in the company, valued at $6,989,297.80. This represents a 7.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, CEO Yvonne Greenstreet sold 6,799 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $2,227,692.35. Following the completion of the sale, the chief executive officer directly owned 98,628 shares of the company's stock, valued at approximately $32,315,464.20. This represents a 6.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 21,255 shares of company stock valued at $6,930,337 over the last ninety days. Company insiders own  0.86% of the company's stock. </p><h2>Hedge Funds Weigh In On Alnylam Pharmaceuticals</h2><p>Hedge funds have recently bought and sold shares of the business. Janus Henderson Group PLC grew its stake in  Alnylam Pharmaceuticals by 7.8% in the 1st quarter. Janus Henderson Group PLC now owns 147,089 shares of the biopharmaceutical company's stock valued at $48,661,000 after buying an additional 10,664 shares during the last quarter.  Oddo BHF Asset Management Sas boosted its holdings in  Alnylam Pharmaceuticals by 9.6% during the first quarter. Oddo BHF Asset Management Sas now owns 33,013 shares of the biopharmaceutical company's stock valued at $10,923,000 after acquiring an additional 2,880 shares during the period.  Bull Harbor Capital LLC bought a new stake in  Alnylam Pharmaceuticals during the first quarter valued at about $210,000.  Rock Springs Capital Management LP grew its position in shares of  Alnylam Pharmaceuticals by 3.9% in the first quarter. Rock Springs Capital Management LP now owns 74,000 shares of the biopharmaceutical company's stock valued at $24,484,000 after purchasing an additional 2,750 shares during the last quarter.  Finally, Quantinno Capital Management LP grew its position in shares of  Alnylam Pharmaceuticals by 32.3% in the first quarter. Quantinno Capital Management LP now owns 33,850 shares of the biopharmaceutical company's stock valued at $11,200,000 after purchasing an additional 8,258 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds. </p><h2>Alnylam Pharmaceuticals Stock Performance</h2><ul><li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li></ul><p>NASDAQ ALNY opened at $294.30 on Wednesday. The company has a market capitalization of $39.29 billion, a PE ratio of 80.41 and a beta of 0.31. Alnylam Pharmaceuticals has a twelve month low of $284.19 and a twelve month high of $495.55. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. The business's 50-day moving average price is $312.56 and its 200 day moving average price is $362.08. </p><p>Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating analysts' consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The firm had revenue of $1.17 billion for the quarter, compared to analysts' expectations of $1.12 billion. During the same quarter last year, the firm earned ($0.44) earnings per share. The firm's revenue for the quarter was up 96.4% compared to the same quarter last year.  On average, research analysts predict that  Alnylam Pharmaceuticals will post 7.36 earnings per share for the current year. </p><h2>About Alnylam Pharmaceuticals</h2> (Get Free Report)<p>Alnylam Pharmaceuticals, Inc <span>NASDAQ: ALNY<span></span></span> is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.  </p><p>Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Alnylam Pharmaceuticals</li><li>HIVE Weaponizes Power for an AI Pivot</li><li>A Deep Dive Into NVIDIA’s Latest Portfolio Moves</li><li>Brady Corp Wires Up a Massive AI-Powered Breakout</li><li>Why Home Depot’s Sell-Off Could Become a Huge Opportunity</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Alnylam Pharmaceuticals Right Now?</h2><p>Before you consider Alnylam Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.</p><p>While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ALNY

<p>Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has received a consensus rating of 'Moderate Buy' from 26 research firms. Analysts' ratings include six holds, nineteen buys, and one strong buy. The average 12-month price target is $463.13. Recent insider sales include EVP Kevin Fitzgerald and CEO Yvonne Greenstreet, who sold shares valued at over $2.7 million. Institutional investors own 92.97% of the stock, which opened at $294.30 with a market cap of $39.29 billion.</p>

Market Beat

Alnylam Pharma

iShares US Pharma

SPDR S&P Biotech

Direxion Daily Biotech Top 5 Bull 2X ETF

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

VG Health

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Citigroup

Truist Financial

Janus Henderson

Argenx

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Recommendation of "Moderate Buy" by Analysts